Skip to content

Therapeutic efficacy of jiawei Chuanxiong chatiao san and Fengchi acupoint with Wentong acupuncture in the treatment of migraine without aura and fMRI study of brain

Therapeutic efficacy of jiawei Chuanxiong chatiao san and Fengchi acupoint with Wentong acupuncture in the treatment of migraine without aura and fMRI study of brain

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000841
Enrollment
Unknown
Registered
2025-04-24
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine without aura

Interventions

Wentong Acupuncture and Medicine Group:Wentong Acupuncture at the Fengchi point and oral Modified Chuanxiong Chatiao San
Wentong Acupuncture Group:Wentong Acupuncture at the Fengchi point
Wentong Medicine Group: oral Modified Chuanxiong Chatiao San
Control Group:Oral Modified Chuanxiong Chatiao San simulant

Sponsors

Beijing University of Chinese Medicine Third Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Clinical symptoms meeting the diagnostic criteria for migraine without aura; (2) Age between 18-65 years old gender-neutral right-handed; (3) Age of first attack <50 years duration of disease =1 year; (4) The average number of headache attack days per month in the last 3 months was 2-14 days; (5) Study participants with headache attacks of moderate to severe pain (mean VAS score of 4-10); (6) Those who were able to sign the informed consent fill in the headache diary and cooperated in completing the treatment and follow-up visits.

Exclusion criteria

Exclusion criteria: (1) Combined with other primary headache secondary headache and other headache with unknown diagnosis; (2) Those who have a combination of serious primary diseases such as cardiovascular cerebrovascular hepatic renal and hematopoietic systems and other organic lesions; (3) Those with confirmed diagnosis of serious mental disorders such as schizophrenia schizoaffective disorder paranoid psychosis bipolar disorder mental disorder due to epilepsy mental retardation with mental disorder etc; (4) Those with intellectual disabilities who cannot cooperate in completing the questionnaire; (5) Nursing women pregnant or planning to be pregnant; (6) Those who have been taking painkillers for a long time or those who are dependent on painkillers (taking painkillers for more than 15 days in 1 month); (7) Those who have taken medications with clear prophylactic therapeutic effects for migraine within 4 weeks; (8) Those who are allergic to any of the ingredients in the Chinese medicine formula granules used in this study or cannot accept acupuncture; (9) Those who have participated in a clinical study related to migraine preventive treatment within 3 months. (10) Have contraindications to MRI: pacemaker claustrophobia etc; (11) Those with any cranial deformity and intracranial lesions.

Design outcomes

Primary

MeasureTime frame
Migraine Days;

Secondary

MeasureTime frame
Headache Impact Test (HIT-6);Response rate;Migraine-Specific Quality-of-Life Questionnaire(MSQ);Acute analgesic drug treatment frequency;Migraine Duration;Hospital anxiety and depression scale(HADS);visual analogue scale(VAS);Work Productivity and Activity Impairment Questionnaire:Migraine(WPAI);Migraine Attacks;

Countries

China

Contacts

Public ContactZhao Yonglie

Beijing University of Chinese Medicine Third Affiliated Hospital

yongy3@126.com+86 13641086409

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026